SMA Capital’s Viridian Therapeutics VRDN Stock Holding History

SMA Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-203	Closed	-$3.97K	–	170
2026 Q1	$3.97K	Buy	+203	New	+$6.03K	﹤0.01%	94

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SMA Capital's VRDN Position: Q2 2026 in Review

SMA Capital sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 203 shares — an estimated $3.97K sold.

SMA Capital first reported a position in VRDN in Q1 2026 and held it in 1 quarter. The position peaked at $3.97K in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

SMA Capital reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 203 Viridian Therapeutics shares in Q2 2026, an estimated $3.97K.
SMA Capital first reported a position in Viridian Therapeutics in Q1 2026 and held it in 1 quarter.
SMA Capital's Viridian Therapeutics position peaked at $3.97K in Q1 2026.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.